Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Agius, K. Lacy, M. Vukmanovic‐Stejic, A. Papageorgiou, S. Hall, Reed, J. Curnow, L. Taams, A. Jagger, J. Fuentes-Duculan, C. Buckley, M. Salmon, J. Krueger, J. Greenwood, N. Klein, M. Rustin, A. Akbar (2010)
Decreased TNF-alpha synthesis by macrophages restricts cutaneous immunosurveillance by memory CD4(+) T cells during ageing
C. Balch, J. Gershenwald, S. Soong, J. Thompson, M. Atkins, D. Byrd, A. Buzaid, A. Cochran, D. Coit, Shouluan Ding, A. Eggermont, K. Flaherty, P. Gimotty, J. Kirkwood, K. McMasters, M. Mihm, D. Morton, M. Ross, A. Sober, V. Sondak (2009)
Final version of 2009 AJCC melanoma staging and classification.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 36
Claudia Geldres, B. Savoldo, V. Hoyos, Ignazio Caruana, Ming Zhang, E. Yvon, M. Vecchio, C. Creighton, M. Ittmann, S. Ferrone, G. Dotti (2013)
T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In VivoClinical Cancer Research, 20
G. Bollag, J. Tsai, Jiazhong Zhang, Chao Zhang, P. Ibrahim, K. Nolop, P. Hirth (2012)
Vemurafenib: the first drug approved for BRAF-mutant cancerNature Reviews Drug Discovery, 11
X. Yao, M. Ahmadzadeh, Yong-Chen Lu, D. Liewehr, M. Dudley, Fang Liu, D. Schrump, S. Steinberg, S. Rosenberg, P. Robbins (2012)
Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.Blood, 119 24
C. Robert, L. Thomas, I. Bondarenko, S. O'Day, J. Weber, C. Garbe, C. Lebbé, J. Baurain, A. Testori, J. Grob, N. Davidson, J. Richards, M. Maio, A. Hauschild, W. Miller, P. Gascón, M. Lotem, K. Harmankaya, R. Ibrahim, S. Francis, Tai-Tsang Chen, R. Humphrey, A. Hoos, J. Wolchok (2011)
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.The New England journal of medicine, 364 26
M. Kusama, T. Kageshita, Z. Chen, S. Ferrone (1989)
Characterization of syngeneic antiidiotypic monoclonal antibodies to murine anti-human high molecular weight melanoma-associated antigen monoclonal antibodies.Journal of immunology, 143 11
H. Torisu-Itakura, H. Schoellhammer, M. Sim, R. Irie, S. Hausmann, Tobias Raum, P. Baeuerle, D. Morton (2011)
Redirected Lysis of Human Melanoma Cells by a MCSP/CD3-bispecific BiTE Antibody That Engages Patient-derived T CellsJournal of Immunotherapy, 34
K. Peggs, S. Quezada, C. Chambers, A. Korman, J. Allison (2009)
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodiesThe Journal of Experimental Medicine, 206
Jianda Yuan, G. Ku, H. Gallardo, F. Orlandi, G. Manukian, T. Rasalan, Yinyan Xu, Hao-Kang Li, S. Vyas, Z. Mu, P. Chapman, S. Krown, K. Panageas, S. Terzulli, L. Old, A. Houghton, J. Wolchok (2009)
Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma.Cancer immunity, 9
A. Ribas, R. Kefford, M. Marshall, C. Punt, J. Haanen, M. Mármol, C. Garbe, H. Gogas, J. Schachter, G. Linette, P. Lorigan, K. Kendra, M. Maio, U. Trefzer, M. Smylie, G. McArthur, B. Dréno, P. Nathan, J. Mackiewicz, J. Kirkwood, J. Gómez-Navarro, B. Huang, D. Pavlov, A. Hauschild (2013)
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 5
S. Tsoka, C. Ainali, P. Karagiannis, D. Josephs, L. Saul, F. Nestle, S. Karagiannis (2012)
Toward prediction of immune mechanisms and design of immunotherapies in melanoma.Critical reviews in biomedical engineering, 40 4
Eggermont (2008)
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trialLancet, 372
Xinhui Wang, T. Osada, Yangyang Wang, Ling Yu, K. Sakakura, A. Katayama, J. McCarthy, A. Brufsky, M. Chivukula, T. Khoury, D. Hsu, William Barry, H. Lyerly, T. Clay, S. Ferrone (2010)
CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.Journal of the National Cancer Institute, 102 19
Kirkwood (1996)
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684J Clin Oncol, 14
T. Fujimura, S. Ring, V. Umansky, K. Mahnke, A. Enk (2012)
Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas.The Journal of investigative dermatology, 132 4
J. Dannull, N. Haley, G. Archer, S. Nair, D. Boczkowski, Mark Harper, Nicole Rosa, N. Pickett, P. Mosca, J. Burchette, M. Selim, D. Mitchell, J. Sampson, D. Tyler, Scott Pruitt (2013)
Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.The Journal of clinical investigation, 123 7
S. Topalian, M. Sznol, D. McDermott, H. Kluger, R. Carvajal, W. Sharfman, J. Brahmer, D. Lawrence, M. Atkins, J. Powderly, P. Leming, E. Lipson, I. Puzanov, David Smith, J. Taube, J. Wigginton, G. Kollia, A. Gupta, D. Pardoll, J. Sosman, F. Hodi (2014)
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 10
M. Postow, M. Callahan, J. Wolchok (2012)
The Antitumor Immunity of Ipilimumab: (T-cell) Memories to Last a Lifetime?Clinical Cancer Research, 18
A. Gilbert, P. Karagiannis, T. Dodev, A. Koers, K. Lacy, D. Josephs, Pooja Takhar, J. Geh, C. Healy, M. Harries, K. Acland, S. Rudman, R. Beavil, P. Blower, A. Beavil, H. Gould, J. Spicer, F. Nestle, S. Karagiannis (2011)
Monitoring the Systemic Human Memory B Cell Compartment of Melanoma Patients for Anti-Tumor IgG AntibodiesPLoS ONE, 6
M. Ahmadzadeh, L. Johnson, B. Heemskerk, J. Wunderlich, M. Dudley, D. White, S. Rosenberg (2009)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.Blood, 114 8
A. Cipponi, Grégoire Wieers, N. Baren, P. Coulie (2011)
Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?Cancer Immunology, Immunotherapy, 60
J. Reichert, Eugen Dhimolea (2012)
The future of antibodies as cancer drugs.Drug discovery today, 17 17-18
Jianbo Yang, M. Price, C. Neudauer, Christopher Wilson, S. Ferrone, H. Xia, J. Iida, M. Simpson, J. McCarthy (2004)
Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanismsThe Journal of Cell Biology, 165
E. Hersh, S. O'Day, J. Powderly, K. Khan, A. Pavlick, L. Cranmer, W. Samlowski, G. Nichol, M. Yellin, J. Weber (2011)
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanomaInvestigational New Drugs, 29
M. Bruyn, A. Rybczynska, Yunwei Wei, Michael Schwenkert, G. Fey, R. Dierckx, A. Waarde, W. Helfrich, E. Bremer (2010)
Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivoMolecular Cancer, 9
Tao Wang, Yingbin Ge, M. Xiao, Alfonso López-Coral, Rikka Azuma, R. Somasundaram, Gao Zhang, Zhi Wei, Xiaowei Xu, F. Rauscher, M. Herlyn, Russel Kaufman (2012)
Melanoma‐derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signaturePigment Cell & Melanoma Research, 25
B. Hillner (1998)
Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma.European journal of cancer, 34 Suppl 3
R. Bart, N. Porzio, A. Kopf, J. Vilček, E. Cheng, Y. Farcet (1980)
Inhibition of growth of B16 murine malignant melanoma by exogenous interferon.Cancer research, 40 3
P. Ascierto, E. Simeone, D. Giannarelli, A. Grimaldi, A. Romano, N. Mozzillo (2012)
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical useJournal of Translational Medicine, 10
J. Jacobs, J. Cornelis, Punt, W. Lesterhuis, R. Sutmuller, Mary-Lène Brouwer, N. Scharenborg, I. Klasen, L. Hilbrands, C. Figdor, I. Jolanda, M. Vries, G. Adema (2010)
Clinical Cancer esearch cer Therapy : Clinical dritic Cell Vaccination in Combination with Anti-CD 25 oclonal Antibody Treatment : A Phase I / II Study in R astatic Melanoma Patients
(2014)
ONCOLOGY REPORTS
M. Atkins, M. Lotze, J. Dutcher, R. Fisher, G. Weiss, K. Margolin, J. Abrams, M. Sznol, D. Parkinson, M. Hawkins, C. Paradise, L. Kunkel, S. Rosenberg (1999)
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 7
M. Atkins (2006)
Cytokine-Based Therapy and Biochemotherapy for Advanced MelanomaClinical Cancer Research, 12
Kerrington Molhoek, H. Griesemann, Jianfen Shu, J. Gershenwald, D. Brautigan, C. Slingluff (2008)
Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2.Cancer research, 68 11
D. Perez, V. Suman, T. Fitch, T. Amatruda, R. Morton, S. Jilani, C. Constantinou, J. Egner, L. Kottschade, S. Markovic (2009)
Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanomaCancer, 115
D. Oble, R. Loewe, P. Yu, M. Mihm (2009)
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.Cancer immunity, 9
Kory Alderson, M. Luangrath, Megan Elsenheimer, S. Gillies, F. Navid, A. Rakhmilevich, P. Sondel (2013)
Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpGCancer Immunology, Immunotherapy, 62
Petrella (2007)
Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic reviewCancer Treat Rev, 33
J. Mehnert, M. McCarthy, Lucia Jilaveanu, K. Flaherty, S. Aziz, R. Camp, D. Rimm, H. Kluger (2010)
Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays.Human pathology, 41 3
A. Mittelman, X. Wang, K. Matsumoto, S. Ferrone (1995)
Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23.Hybridoma, 14 2
M. Cheever, C. Higano (2011)
PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer VaccineClinical Cancer Research, 17
K. Silina, U. Rulle, Z. Kalnina, A. Linē (2014)
Manipulation of tumour-infiltrating B cells and tertiary lymphoid structures: a novel anti-cancer treatment avenue?Cancer Immunology, Immunotherapy, 63
S. Ngiow, D. Knight, A. Ribas, G. McArthur, M. Smyth (2013)
BRAF-targeted therapy and immune responses to melanomaOncoimmunology, 2
F. Spinella, Valentina Caprara, Roberta Cianfrocca, L. Rosanò, V. Castro, E. Garrafa, P. Natali, A. Bagnato (2014)
The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor.Carcinogenesis, 35 4
A. Hauschild, J. Grob, L. Demidov, T. Jouary, R. Gutzmer, M. Millward, P. Rutkowski, C. Blank, W. Miller, E. Kaempgen, S. Martı́n-Algarra, B. Karaszewska, C. Mauch, V. Chiarion-Sileni, Anne-Marie Martin, S. Swann, P. Haney, B. Mirakhur, Mary Guckert, V. Goodman, P. Chapman (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialThe Lancet, 380
J. Murray, Michael Gillogly, K. Kawano, C. Efferson, Jeffrey Lee, M. Ross, Xinhui Wang, S. Ferrone, C. Ioannides (2004)
Fine Specificity of High Molecular Weight-Melanoma-Associated Antigen-Specific Cytotoxic T Lymphocytes Elicited by Anti-Idiotypic Monoclonal Antibodies in Patients with MelanomaCancer Research, 64
J. Hsu, H. Wakelee (2012)
Monoclonal Antibodies Targeting Vascular Endothelial Growth FactorBioDrugs, 23
A. Mittelman, Z. Chen, Hong Yang, G. Wong, S. Ferrone (1992)
Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma.Proceedings of the National Academy of Sciences of the United States of America, 89 2
J. Kirkwood, M. Strawderman, M. Ernstoff, T. Smith, E. Borden, R. Blum (2023)
Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684Journal of Clinical Oncology, 41
L. Ly, M. Sluijter, S. Burg, M. Jager, T. Hall (2013)
Effective Cooperation of Monoclonal Antibody and Peptide Vaccine for the Treatment of Mouse MelanomaThe Journal of Immunology, 190
A. Ribas, L. Camacho, G. Lopez-Berestein, D. Pavlov, C. Bulanhagui, R. Millham, B. Comin-Anduix, J. Reuben, E. Seja, C. Parker, Amarnath Sharma, J. Glaspy, J. Gómez-Navarro (2005)
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 35
J. Weber, S. O'Day, W. Urba, J. Powderly, G. Nichol, M. Yellin, J. Snively, E. Hersh (2008)
Phase I/II study of ipilimumab for patients with metastatic melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 36
K. Guenterberg, V. Grignol, Kiran Relekar, K. Varker, Helen Chen, K. Kendra, T. Olencki, W. Carson (2011)
A Pilot Study of Bevacizumab and Interferon-&agr;2b in Ocular MelanomaAmerican Journal of Clinical Oncology, 34
J. Brahmer, C. Drake, I. Wollner, J. Powderly, J. Picus, W. Sharfman, E. Stankevich, A. Pons, Theresa Salay, T. McMiller, Marta Gilson, Changyu Wang, M. Selby, J. Taube, R. Anders, Lieping Chen, A. Korman, D. Pardoll, I. Lowy, S. Topalian (2010)
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 19
E. Borden (1992)
Interferons: pleiotropic cellular modulators.Clinical immunology and immunopathology, 62 1 Pt 2
O. Hamid, C. Robert, A. Daud, F. Hodi, W. Hwu, R. Kefford, J. Wolchok, P. Hersey, R. Joseph, J. Weber, R. Dronca, T. Gangadhar, A. Patnaik, H. Zarour, A. Joshua, K. Gergich, J. Elassaiss-Schaap, A. Algazi, C. Mateus, P. Boasberg, P. Tumeh, B. Chmielowski, S. Ebbinghaus, Xiaoyun Li, S. Kang, A. Ribas (2013)
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.The New England journal of medicine, 369 2
S. Lohse, S. Derer, T. Beyer, K. Klausz, M. Peipp, J. Leusen, J. Winkel, M. Dechant, T. Valerius (2011)
Recombinant Dimeric IgA Antibodies against the Epidermal Growth Factor Receptor Mediate Effective Tumor Cell KillingThe Journal of Immunology, 186
M. Gordon (2009)
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trialYearbook of Medicine, 2009
E. Perez, D. Hillman, T. Dentchev, N. Le-Lindqwister, L. Geeraerts, T. Fitch, Heshan Liu, D. Graham, S. Kahanic, H. Gross, T. Patel, F. Palmieri, A. Dueck (2010)
North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 21 2
Cameron Wright, P. McCormack (2013)
Trametinib: First Global ApprovalDrugs, 73
E. Agius, K. Lacy, M. Vukmanovic‐Stejic, A. Jagger, A. Papageorgiou, S. Hall, J. Reed, S. Curnow, J. Fuentes-Duculan, C. Buckley, M. Salmon, L. Taams, J. Krueger, J. Greenwood, N. Klein, M. Rustin, A. Akbar (2009)
Decreased TNF-α synthesis by macrophages restricts cutaneous immunosurveillance by memory CD4+ T cells during agingThe Journal of Experimental Medicine, 206
P. Maciag, M. Seavey, Z. Pan, S. Ferrone, Y. Paterson (2008)
Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature.Cancer research, 68 19
D. Knight, S. Ngiow, Ming Li, Tiffany Parmenter, Stephen Mok, Ashley Cass, N. Haynes, K. Kinross, H. Yagita, R. Koya, T. Graeber, A. Ribas, G. McArthur, M. Smyth (2013)
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.The Journal of clinical investigation, 123 3
P. Linsley, W. Brady, Mark Urnes, L. Grosmaire, N. Damle, J. Ledbetter (1991)
CTLA-4 is a second receptor for the B cell activation antigen B7The Journal of Experimental Medicine, 174
K. Azijli, E. Stelloo, G. Peters, A. Eertwegh (2014)
New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.Anticancer research, 34 4
S. Karagiannis, D. Josephs, P. Karagiannis, A. Gilbert, L. Saul, S. Rudman, T. Dodev, A. Koers, P. Blower, C. Corrigan, A. Beavil, J. Spicer, F. Nestle, H. Gould (2012)
Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical applicationCancer Immunology, Immunotherapy, 61
C. Miracco, V. Mourmouras, M. Biagioli, P. Rubegni, S. Mannucci, I. Monciatti, E. Cosci, P. Tosi, P. Luzi (2007)
Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma.Oncology reports, 18 5
K. Varker, J. Biber, C. Kefauver, R. Jensen, A. Lehman, D. Young, Haifeng Wu, G. Lesinski, K. Kendra, Helen Chen, M. Walker, William III (2007)
A Randomized Phase 2 Trial of Bevacizumab with or without Daily Low-Dose Interferon Alfa-2b in Metastatic Malignant MelanomaAnnals of Surgical Oncology, 14
A. Ribas, F. Hodi, M. Callahan, C. Konto, J. Wolchok (2013)
Hepatotoxicity with combination of vemurafenib and ipilimumab.The New England journal of medicine, 368 14
T. Simpson, Fubin Li, Welby Montalvo-Ortiz, Manuel Sepulveda, K. Bergerhoff, F. Arce, C. Roddie, J. Henry, H. Yagita, J. Wolchok, K. Peggs, J. Ravetch, J. Allison, S. Quezada (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanomaThe Journal of Experimental Medicine, 210
Yannick Bulliard, R. Jolicoeur, Maurice Windman, Sarah Rue, Seth Ettenberg, D. Knee, N. Wilson, G. Dranoff, J. Brogdon (2013)
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodiesThe Journal of Experimental Medicine, 210
P. Corrie, A. Marshall, J. Dunn, M. Middleton, P. Nathan, M. Gore, N. Davidson, S. Nicholson, C. Kelly, M. Marples, S. Danson, E. Marshall, S. Houston, R. Board, A. Waterston, J. Nobes, M. Harries, Satish Kumar, G. Young, P. Lorigan (2014)
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.The Lancet. Oncology, 15 6
M. Price, Leah Wanshura, Jianbo Yang, J. Carlson, Bo Xiang, Gui-yuan Li, S. Ferrone, A. Dudek, E. Turley, J. McCarthy (2011)
CSPG4, a potential therapeutic target, facilitates malignant progression of melanomaPigment Cell & Melanoma Research, 24
Z. Chen, H. Yang, T. Kageshita, S. Ferrone (1991)
Human high-molecular-weight melanoma-associated antigen mimicry by mouse antiidiotypic monoclonal antibody TK7-371.Cancer research, 51 18
A. Rybczynska, R. Dierckx, K. Ishiwata, P. Elsinga, A. Waarde (2008)
Cytotoxicity of σ-Receptor Ligands Is Associated with Major Changes of Cellular Metabolism and Complete Occupancy of the σ-2 SubpopulationJournal of Nuclear Medicine, 49
J. Allison, C. Chambers, A. Hurwitz, T. Sullivan, B. Boitel, S. Fournier, M. Brunner, M. Krummel (2007)
A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance?Novartis Foundation symposium, 215
M. Vecchio, R. Mortarini, S. Canova, L. Guardo, N. Pimpinelli, M. Sertoli, D. Bedognetti, P. Queirolo, P. Morosini, T. Perrone, E. Bajetta, A. Anichini (2010)
Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis FactorsClinical Cancer Research, 16
J. Wolchok, H. Kluger, M. Callahan, M. Postow, N. Rizvi, A. Lesokhin, N. Segal, C. Ariyan, R. Gordon, Kathleen Reed, M. Burke, A. Caldwell, S. Kronenberg, B. Agunwamba, Xiaoling Zhang, I. Lowy, H. Inzunza, W. Feely, C. Horak, Q. Hong, A. Korman, J. Wigginton, A. Gupta, M. Sznol (2013)
Nivolumab plus ipilimumab in advanced melanoma.The New England journal of medicine, 369 2
J. Woof (2012)
Insights from Fc receptor biology: A route to improved antibody reagentsmAbs, 4
R. Shrimali, Zhiya Yu, M. Theoret, D. Chinnasamy, N. Restifo, S. Rosenberg (2010)
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.Cancer research, 70 15
A. Hauschild (2009)
Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?Current Oncology, 16
A. Shimanovsky, Ashif Jethava, C. Dasanu (2013)
Immune alterations in malignant melanoma and current immunotherapy conceptsExpert Opinion on Biological Therapy, 13
R. Gerner, G. Moore, C. Dickey (1975)
Combination chemotherapy in disseminated melanoma and other solid tumors in adults.Oncology, 31 1
M. Callahan, M. Postow, J. Wolchok (2013)
Immunomodulatory therapy for melanoma: ipilimumab and beyond.Clinics in dermatology, 31 2
J. Brahmer, S. Tykodi, L. Chow, W. Hwu, S. Topalian, P. Hwu, C. Drake, L. Camacho, J. Kauh, K. Odunsi, H. Pitot, O. Hamid, S. Bhatia, R. Martins, K. Eaton, Shuming Chen, Theresa Salay, S. Alaparthy, J. Grosso, A. Korman, S. Parker, S. Agrawal, S. Goldberg, D. Pardoll, A. Gupta, J. Wigginton (2012)
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.The New England journal of medicine, 366 26
Jianbo Yang, M. Price, Gui-yuan Li, M. Bar‐eli, R. Salgia, Ramasamy Jagedeeswaran, J. Carlson, S. Ferrone, E. Turley, J. McCarthy (2009)
Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition.Cancer research, 69 19
A. Sasse, E. Sasse, L. Clark, Lucia Ulloa, Otávio Clark (2007)
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.The Cochrane database of systematic reviews, 1
(2014)
IgE immunotherapy: a novel concept with promise for the treatment of cancer
G. Phan, J. Yang, R. Sherry, P. Hwu, S. Topalian, D. Schwartzentruber, N. Restifo, Leah Haworth, C. Seipp, Linda Freezer, K. Morton, S. Mavroukakis, P. Duray, S. Steinberg, J. Allison, T. Davis, S. Rosenberg (2003)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanomaProceedings of the National Academy of Sciences of the United States of America, 100
Randall Friedline, David Brown, Hai Nguyen, H. Kornfeld, Jinhee Lee, Yi Zhang, M. Appleby, S. Der, Joonsoo Kang, C. Chambers (2009)
CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic toleranceThe Journal of Experimental Medicine, 206
Jacobs (2010)
Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase III study in metastatic melanoma patientsClin Cancer Res, 16
K. Flaherty (2012)
Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsetsClinical & Experimental Metastasis, 29
E. McCormack, K. Adams, N. Hassan, Akhil Kotian, N. Lissin, Malkit Sami, Maja Mujić, Tereza Osdal, B. Gjertsen, D. Baker, A. Powlesland, M. Aleksić, A. Vuidepot, O. Morteau, Deborah Sutton, C. June, M. Kalos, R. Ashfield, B. Jakobsen (2012)
Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumorsCancer Immunology, Immunotherapy, 62
M. Chekenya, C. Krakstad, A. Svendsen, I. Netland, Vidar Staalesen, B. Tysnes, F. Selheim, Jian Wang, P. Sakariassen, T. Sandal, P. Lønning, T. Flatmark, P. Enger, R. Bjerkvig, M. Sioud, W. Stallcup (2008)
The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signalingOncogene, 27
P. Chapman, A. Hauschild, C. Robert, J. Larkin, J. Haanen, A. Ribas, D. Hogg, O. Hamid, P. Ascierto, A. Testori, P. Lorigan, R. Dummer, J. Sosman, C. Garbe, M. Maio, K. Nolop, B. Nelson, A. Joe, K. Flaherty, G. McArthur (2012)
Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma .Journal of Clinical Oncology, 30
Anita Ballantyne, Karly Garnock-jones (2013)
Dabrafenib: First Global ApprovalDrugs, 73
K. Lacy, S. Karagiannis, F. Nestle (2012)
Advances in the treatment of melanoma.British medical journal, 1 5490
P. Karagiannis, A. Gilbert, F. Nestle, S. Karagiannis (2013)
IgG4 antibodies and cancer-associated inflammationOncoimmunology, 2
F. Hodi, S. O'Day, D. McDermott, R. Weber, J. Sosman, J. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, Jessica Hassel, W. Akerley, A. Eertwegh, J. Lutzky, P. Lorigan, J. Vaubel, G. Linette, D. Hogg, C. Ottensmeier, C. Lebbé, C. Peschel, I. Quirt, Joseph Clark, J. Wolchok, J. Weber, Jason Tian, M. Yellin, G. Nichol, A. Hoos, W. Urba (2010)
Improved survival with ipilimumab in patients with metastatic melanoma.The New England journal of medicine, 363 8
M. Curran, Welby Montalvo, H. Yagita, J. Allison (2010)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProceedings of the National Academy of Sciences, 107
A. Mittelman, George Chen, G. Wong, Chang-Jie Liu, S. Hirai, S. Ferrone (1995)
Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research, 1 7
D. Zikich, J. Schachter, M. Besser (2013)
Immunotherapy for the Management of Advanced Melanoma: The Next StepsAmerican Journal of Clinical Dermatology, 14
T. Petrella, I. Quirt, S. Verma, A. Haynes, M. Charette, K. Bak (2007)
Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review.Cancer treatment reviews, 33 5
E. Lipson, W. Sharfman, C. Drake, I. Wollner, J. Taube, R. Anders, Haiying Xu, Sheng Yao, A. Pons, Lieping Chen, D. Pardoll, J. Brahmer, S. Topalian (2012)
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 AntibodyClinical Cancer Research, 19
A. Cipponi, M. Mercier, T. Seremet, J. Baurain, I. Theate, J. Oord, M. Stas, T. Boon, P. Coulie, N. Baren (2012)
Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases.Cancer research, 72 16
M. Sznol (2012)
Advances in the treatment of metastatic melanoma: new immunomodulatory agents.Seminars in oncology, 39 2
R. Hino, K. Kabashima, Y. Kato, H. Yagi, Motonobu Nakamura, T. Honjo, Taku Okazaki, Y. Tokura (2010)
Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanomaCancer, 116
S. Lohse, C. Brunke, S. Derer, M. Peipp, P. Boross, C. Kellner, T. Beyer, M. Dechant, Jan Winkel, J. Leusen, T. Valerius (2012)
Characterization of a Mutated IgA2 Antibody of the m(1) Allotype against the Epidermal Growth Factor Receptor for the Recruitment of Monocytes and Macrophages*The Journal of Biological Chemistry, 287
Yoshiko Iwai, Masayoshi Ishida, Yoshimasa Tanaka, Taku Okazaki, T. Honjo, N. Minato (2002)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockadeProceedings of the National Academy of Sciences of the United States of America, 99
G. Scarpati, C. Fusciello, F. Perri, F. Sabbatino, S. Ferrone, C. Carlomagno, S. Pepe (2014)
Ipilimumab in the treatment of metastatic melanoma: management of adverse eventsOncoTargets and therapy, 7
G. Bossi, S. Buisson, Joanne Oates, B. Jakobsen, N. Hassan (2014)
ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cellsCancer Immunology, Immunotherapy, 63
P. Karagiannis, A. Gilbert, D. Josephs, N. Ali, T. Dodev, L. Saul, I. Correa, L. Roberts, E. Beddowes, A. Koers, C. Hobbs, Silvia Ferreira, J. Geh, C. Healy, M. Harries, K. Acland, P. Blower, T. Mitchell, D. Fear, J. Spicer, K. Lacy, F. Nestle, S. Karagiannis (2013)
IgG4 subclass antibodies impair antitumor immunity in melanomaJournal of Clinical Investigation, 123
K. Wheatley, N. Ives, B. Hancock, M. Gore, A. Eggermont, S. Suciu (2003)
Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials.Cancer treatment reviews, 29 4
G. panfilis, N. Campanini, M. Santini, Giovanni Mori, E. Tognetti, R. Maestri, M. Lombardi, E. Froio, D. Ferrari, R. Ricci (2008)
Phase- and stage-related proportions of T cells bearing the transcription factor FOXP3 infiltrate primary melanoma.The Journal of investigative dermatology, 128 3
P. Boross, S. Lohse, Maaike Nederend, J. Jansen, Geert Tetering, M. Dechant, M. Peipp, L. Royle, L. Liew, L. Boon, N. Rooijen, W. Bleeker, P. Parren, J. Winkel, T. Valerius, J. Leusen (2013)
IgA EGFR antibodies mediate tumour killing in vivoEMBO Molecular Medicine, 5
K. Culos, S. Cuéllar (2013)
Novel Targets in the Treatment of Advanced Melanoma: New First-Line Treatment OptionsAnnals of Pharmacotherapy, 47
The interface between malignant melanoma and patient immunity has long been recognised and efforts to treat this most lethal form of skin cancer by activating immune responses with cytokine, vaccine and also antibody immunotherapies have demonstrated promise in limited subsets of patients. In the present study, we discuss different antibody immunotherapy approaches evaluated in the context of melanoma, each designed to act on distinct targets and to employ different mechanisms to restrict tumour growth and spread. Monoclonal antibodies recognising melanoma-associated antigens such as CSPG4/MCSP and targeting elements of tumour-associated vasculature (VEGF) have constituted long-standing translational approaches aimed at reducing melanoma growth and metastasis. Recent insights into mechanisms of immune regulation and tumour-immune cell interactions have helped to identify checkpoint molecules on immune (CTLA4, PD-1) and tumour (PD-L1) cells as promising therapeutic targets. Checkpoint blockade with antibodies to activate immune responses and perhaps to counteract melanoma-associated immunomodulatory mechanisms led to the first clinical breakthrough in the form of an anti-CTLA4 monoclonal antibody. Novel modalities to target key mechanisms of immune suppression and to redirect potent effector cell subsets against tumours are expected to improve clinical outcomes and to provide previously unexplored avenues for therapeutic interventions.
Oncology Reports – Spandidos Publications
Published: Sep 1, 2014
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.